Kim Hong Duck
Biography
Dr. Kim received his PhD on 1996 from the Department of Pharmaceutical Sciences, University of Tokyo, and Tokyo, Japan. He completed his postdoctoral fellowship training in both academic and biotechnology & pharmaceutical companies in Japan, South Korea and USA. He has experience in several scientific backgrounds in the fields of molecular, neurobiology, cancer pharmacology such as multidrug resistance in solid cancers, vaccine development for AD and infectious disease, and innate immunity in AD. He has been widely respected for his discovery with regard to the development of antibody against beta amyloid in Alzheimer disease (AD) which develops novel antibody as counteract neurotoxicity due to misfolding of beta amyloid protein and demeliolate of Abeta to neuronal cells which results in memory loss.
Research Interest
Dr. Kim’s research interest will serve as a proof of principle to demonstrate whether our novel immune gene therapy modality with good epitope is effective in treating an animal model of AD.